Realyze Intelligence, a technology platform revolutionizing oncology clinical trials and abstraction of real-world data, is thrilled to announce that Michael Finke and Scot Stevens have joined the company’s Board of Directors and that Carolyn Penstein Rose, PhD, will be working with the company as an Advisor. These three champions of healthcare innovation bring deep technical and industry expertise to the Realyze Intelligence team. Collectively, they will help ensure that the Realyze portfolio of solutions can scale to serve even more health systems and, ultimately, patients in 2024 and beyond.
“We are thrilled to welcome Michael and Scot to the Realyze Board of Directors and Carolyn as an Advisor,” said Aaron Brauser, Founder, President, and CEO of Realyze Intelligence. “Their combined experiences, areas of expertise, and records of success will undoubtably support us in creating even greater value for Realyze and achieving our mission.”
Mr. Stevens is the Chief Information Officer and Vice President of UPMC Hillman Cancer Center and UPMC International. To the Realyze board, he brings over 15 years of experience leading technology initiatives at Hillman Cancer Center, one of the leading cancer centers in the United States for research, care, and prevention. Hillman Cancer Center is the only National Cancer Institute (NCI) designated cancer center in western Pennsylvania and ranked among the top ten cancer research institutes in the United States by NCI. Mr. Stevens is a respected leader with extensive knowledge and understanding of the intersection between health care, technology, and cancer treatment.
Mr. Finke is currently the Chief AI Architect at GrowthCurve Capital. For the previous 25 years, he has built an incredible track record of studying, developing, and bringing to market machine-learning, natural language, and speech understanding technologies. In 2001, he co-founded M*Modal where he served as the company’s Chairman and CEO from its founding until 2012 and President from 2011 and through its acquisition in 2019, until 2020. In 2019, M*Modal was acquired by 3M creating the largest artificial intelligence (AI) platform in healthcare. Mr. Finke is a seasoned executive with invaluable experience in the healthcare technology industry.
Dr. Rose is a renowned expert in the field of artificial intelligence and education, with a focus on computational modeling of discourse to enable scientific understanding of the social and pragmatic nature of learning. She is currently at Carnegie Mellon University as a Professor of Language Technologies and Human-Computer Interaction and Interim Director of the Language Technologies Institute.
As an Advisor to Realyze Intelligence, Dr. Rose will provide critical insights and guidance on the development of the company’s AI-powered platform. Her expertise in computational modeling of discourse and conversational agents will be beneficial in helping Realyze Intelligence create a platform that supports the company’s mission to scale and accelerate clinical trial matching in a variety of settings.
“We are thrilled to have Dr. Rose join our team as an Advisor,” said Gilan El Saadawi, MD, PhD, MS, Founder and Chief Medical Officer of Realyze Intelligence. “Her expertise in artificial intelligence and human computer interaction will be invaluable as we continue to develop our platform and work towards our mission of improving cancer by applying technology to the process of matching patients to clinical trials.”
Mr. Finke and Mr. Stevens’ appointments to the Board as well as Dr. Rose’s appointment as an Advisor were effective as of November 2023.